UK-based Bespak, one of the two contract manufacturers of Pfizer's
inhaled insulin Exubera, confirmed on Friday it has been approached
by a potential buyer.
UK medical technology producers, Bespak reported healthy sales and
profit figures the first half period, identifying three areas of
prosperity, which could spell future growth within established
markets and opportunities worldwide.
Regulatory demands in the US aimed at improving the devices used to
deliver inhaled drugs have spurred an agreement that could see
Bespak's specialised inhalers rolled out across the world.
Bespak of the UK, a specialist in inhalation devices for drug
delivery, has opened a new £10 million (€15m) facility at its
King's Lynn site for the manufacture of pMDIs.
